What Makes a Biomedical Implant a Desirable Way to Administer PrEP?
JUL 25, 2017 | CONTAGION® EDITORIAL STAFF
Ariane van der Straten, PhD, MPH, Senior Fellow, Women’s Global Health Imperative Program Director, RTI International, USA, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.
Interview Transcript (slightly modified for readability)
“I think it has a lot of potential attributes that would make it very desirable for the end user. First of all, it is gender-neutral; it can be used by men, women, or transgender people because it is not required to be topically applied in the vagina or the rectum. It also would prevent from all modes of exposure to HIV, whether through vaginal, rectal, or parenteral exposure, and so that makes it a prevention method that everyone could use. The other reason why I think it would be a very desirable method is because it is very discreet, actually, it is invisible. We have heard from end-users and participants in trials from the beginning that they had concerns around stigmas of preventing HIV and so a very discreet method would be favorably viewed.
It is a provider-administered method, which means that the user does not have to do anything to be adherent. One of the main reasons why a lot of prevention methods have failed so far, including oral PrEP in certain cases, is because people were not taking the product. They forget to take it, they do not want to take it, they change their mind, but mostly it is because [they forget to take it]. Once you have the implant administered by the provider, you will be protected for the whole time that it delivers the drug.
The final important aspect is duration. People do not want to be burdened by having to remember to come to the clinic every month or to be taking a pill every day. An implant would provide protection for 3 to 6 months, or perhaps even 1 year. That would be a significant advantage, both at an individual level and at a population level for curbing the epidemic.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512